Autologous engineered T cell receptor therapy in advanced cancer

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Adoptive cell therapy (ACT) faces challenges in treating advanced cancers.
• Personalized T-cell therapies offer a promising approach to overcome these limitations.

Purpose of the Study:

• To evaluate the feasibility and efficacy of a personalized autologous T-cell therapy program (IMA101) for patients with advanced cancer.
• To assess the safety and clinical outcomes of IMA101, alone or in combination with atezolizumab.

Main Methods:

• Patients with HLA-A*02:01 allele and specific tumor antigen expression were screened.
• Leukapheresis and T-cell product manufacturing were performed, followed by lymphodepletion and IMA101 infusion with interleukin-2.
• Patients received either IMA101 or IMA101 plus atezolizumab.

Main Results:

• Out of 214 screened patients, 14 were treated.
• The most common adverse events were cytokine release syndrome and cytopenia.
• At 6 weeks, 85.7% of patients had stable disease, with three experiencing prolonged stabilization (7.3-13.7 months).
• Median progression-free survival was 3.4 months, and median overall survival was 9.4 months.
• Target-specific T cells expanded significantly, reaching up to 78.7% of CD8+ cells.

Conclusions:

• IMA101 is a feasible and well-tolerated personalized autologous T-cell therapy.
• Multi-targeted ACT leveraging IMA101 shows potential for advanced cancer treatment.
• Further investigation into IMA101 for cancer therapy is warranted.